BELITE BIO, INC
BLTELoading price...
Overview
Previous Close--
Open--
Ask--
Bid--
Day's Range-- - --
52 Week Range-- - --
PE Ratio(TTM)--
Market Cap--
Volume--
Avg. Volume--
12 Months Earnings-90.27M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 101.38M | 84.21M | 40.00M | 31.67M | 12.82M | 8.56M |
| Profit after Tax (Net Income) | -90.27M | -77.61M | -36.14M | -31.63M | -12.65M | -8.41M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: San Diego, United States
Website: https://www.belitebio.com
Chairman of the Board of Directors & CEO: Dr. Yu-Hsin Lin M.B.A., Ph.D.
Employees: 41
About Company:
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.